Portola Pharmaceuticals (NASDAQ: PTLA) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Portola Pharmaceuticals to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.
Risk and Volatility
Portola Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Portola Pharmaceuticals’ rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Portola Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Portola Pharmaceuticals Competitors||469||2235||6130||118||2.66|
Portola Pharmaceuticals presently has a consensus price target of $67.67, indicating a potential upside of 26.98%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 0.11%. Given Portola Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Portola Pharmaceuticals is more favorable than its rivals.
Institutional & Insider Ownership
85.0% of Portola Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 4.9% of Portola Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Portola Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Portola Pharmaceuticals Competitors||-3,989.66%||-117.88%||-44.45%|
Earnings & Valuation
This table compares Portola Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Portola Pharmaceuticals||$31.93 million||-$251.01 million||-11.71|
|Portola Pharmaceuticals Competitors||$207.83 million||-$2.34 million||0.17|
Portola Pharmaceuticals’ rivals have higher revenue and earnings than Portola Pharmaceuticals. Portola Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Portola Pharmaceuticals rivals beat Portola Pharmaceuticals on 7 of the 12 factors compared.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.